A federal advisory panel unanimously recommended approval of Moderna’s mRNA influenza vaccine on Thursday, June 18, 2026, marking a significant step toward bringing the first messenger RNA flu shot to the U.S. market. The Food and Drug Administration is expected to issue a final decision by early August for use in adults 50 and older.
Regulatory Path and Committee Recommendation
The Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted unanimously that the benefits of Moderna’s shot, known as mFlusiva, outweigh its risks. According to the Associated Press, the FDA is evaluating the vaccine for two distinct groups: those ages 50 to 64, and those 65 and older. While the agency appears ready to license the vaccine for the younger cohort via a traditional pathway, it is considering an accelerated approval pathway for the older demographic, as reported by STAT.
The path to this recommendation was not without friction. Earlier this year, the FDA initially declined to review Moderna’s application, citing the company’s decision to compare its vaccine against standard flu shots rather than the high-dose versions typically recommended for seniors, according to NBC News. The agency eventually reversed that decision. During the meeting, former FDA employee Wellington Sun noted that multiple flu vaccines currently on the market were licensed using the same accelerated pathway.
The accelerated approval process, formalized under the FDA Safety and Innovation Act of 2012, allows the agency to approve drugs for serious conditions based on a surrogate endpoint—a marker that is reasonably likely to predict clinical benefit. In the context of vaccines, this often involves measuring antibody titers rather than waiting for a full count of confirmed infection cases. This regulatory mechanism is a cornerstone of how the FDA manages emerging health threats, allowing for faster access to medical countermeasures while requiring rigorous post-marketing studies to verify the clinical benefit.
Clinical Efficacy and Manufacturing Advantages
The primary advantage touted by proponents of the mRNA platform is speed. Unlike traditional egg-based vaccines, which require months of lead time—often necessitating the selection of flu strains early in the year based on global surveillance—mRNA technology allows for a more rapid turnaround. Moderna executives informed the panel that their manufacturing process takes only two to three months from strain selection to rollout, compared to the six months required for traditional methods.
“The ability to tweak a flu vaccine later in the year than can be done with egg based vaccines may allow more up to date vaccines,” noted Dr. Jesse Goodman, former FDA chief scientist and infectious disease specialist at Georgetown University Medical Center, via NBC News.
In clinical trials, the vaccine demonstrated improved performance over conventional options. A late-stage study of 40,000 participants aged 50 and older showed the mRNA vaccine reduced flu cases by approximately 27% compared to a standard routinely used vaccine. Dr. Anna Durbin of Johns Hopkins University, an FDA adviser, characterized the data showing strong immune reactions as “very compelling,” according to reporting by the Associated Press.
This efficacy profile is critical because influenza viruses are constantly mutating. Traditional vaccines rely on the cultivation of viruses in chicken eggs, a process that can lead to “egg-adaptive mutations,” where the virus changes to better grow in the egg, sometimes rendering the vaccine less effective against the circulating human strain. mRNA vaccines bypass this biological hurdle by using the genetic code of the protein rather than the virus itself, potentially providing a better match to the circulating seasonal strains.
Safety Profile and Future Requirements
While the committee’s vote was unanimous, the approval for older adults comes with a caveat: Moderna must conduct additional large-scale clinical trials post-market. The company plans to enroll 400,000 people aged 65 and older across two flu seasons to further assess performance in frail seniors and those with compromised immune systems. This requirement, known as a Phase 4 study, is a standard regulatory tool used by the FDA to monitor long-term safety and effectiveness in the real-world population, which often includes more diverse health profiles than are represented in initial clinical trials.
Regarding safety, data presented to the panel indicated no major adverse events. Common side effects—including injection-site pain, fatigue, headache, and fever—occurred at rates typical for mRNA-based vaccines. Dr. Hayley Altman-Gans, a pediatrician at Stanford University Medical Center, noted that these temporary reactions are often an indication that “your immune system is responding,” as reported by the Associated Press.
Contextual Hurdles for Public Distribution
Despite the favorable recommendation from the FDA’s scientific advisers, significant institutional and political barriers remain. NBC News reports that the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP), which must provide a formal recommendation before the shots are widely distributed and integrated into public health insurance programs, has been blocked from convening by a federal judge. This legal impasse creates a unique bottleneck; while the FDA determines if a product is safe and effective, the CDC determines how that product is used in the public health system, including recommendations for specific age groups and scheduling.
Furthermore, the broader environment for mRNA research has shifted. The Department of Health and Human Services (HHS) has adopted a more skeptical stance toward the technology, with Secretary Robert F. Kennedy Jr. previously describing mRNA COVID-19 vaccines as “the deadliest vaccine ever made,” according to NBC News. Last year, the department canceled nearly $500 million in funding for mRNA vaccine research. These political headwinds suggest that even with regulatory clearance, the logistical rollout of mFlusiva may face challenges beyond the standard scientific review process.
Historically, the interplay between the FDA and the CDC is designed to be separate: the FDA acts as the gatekeeper for market entry based on scientific data, while the CDC acts as the strategist for implementation. The current judicial intervention regarding the ACIP’s ability to meet introduces a level of uncertainty not typically seen in standard vaccine approvals, effectively leaving the manufacturer, Moderna, with a regulatory “green light” from the FDA while the pathway for public uptake and distribution through federal channels remains suspended.
Find more reporting in our Business section.
